MetaCap

Dyne Therapeutics (DYN) vs SELLAS Life Sciences Group (SLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SELLAS Life Sciences Group (SLS) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 792.8% versus a loss of 26.8%. Over five years, SLS leads with a +94.0% price change compared with +5.4% for DYN. Dyne Therapeutics is the larger company by market cap ($2.90 billion vs $2.78 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DYN-26.82%SLS+792.81%
+1211%+559%-92%
Nov 21, 20251 yearNov 20, 2026
DYN-1.84%SLS+94.86%
+209%+51%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DYN versus SLS key metrics
MetricDYNSLS
Share price$15.50$13.66
Market cap$2.90B$2.78B
1-day change-3.31%-8.08%
YTD return-20.76%+262.33%
1-year return-26.82%+792.81%
5-year return+5.37%+94.03%
EPS (TTM)$-3.62$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-446.21M$-26.86M
52-week high$27.31$24.89
52-week low$14.00$1.39
Distance from 52-week high-43.23%-45.12%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+121.48%+137.92%
Average volume2.94M9.64M
Shares outstanding187.39M203.86M
Employees32213
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLS has outperformed DYN by 819.6 percentage points over the past year.

About Dyne Therapeutics

DYN stock →

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees

About SELLAS Life Sciences Group

SLS stock →

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

DYN vs SLS FAQ

Which is bigger, Dyne Therapeutics or SELLAS Life Sciences Group?

Dyne Therapeutics (DYN) is larger, with a market capitalization of $2.90B compared with $2.78B for SELLAS Life Sciences Group (SLS).

Which stock has performed better over the past year, DYN or SLS?

SLS returned +792.81% over the past 12 months, compared with -26.82% for DYN (price return, excluding dividends). Past performance does not predict future results.

Are Dyne Therapeutics and SELLAS Life Sciences Group in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons